What are the current guidelines for initiating and monitoring testosterone hormone replacement therapy in adult women with hypoactive sexual desire disorder or persistent menopausal symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Current Guidelines for Testosterone Hormone Replacement Therapy in Women

The only evidence-based indication for testosterone therapy in women is for postmenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment 1.

Indications and Patient Selection

Testosterone therapy should be reserved specifically for postmenopausal women with HSDD—defined as persistent lack of sexual desire causing personal distress for at least 6 months—that is not primarily attributable to relationship problems, mental health disorders, or other modifiable factors 1, 2.

Do not diagnose "androgen deficiency syndrome" in women—there is no well-defined syndrome correlating testosterone levels with specific symptoms 3. The diagnosis of HSDD is clinical and symptom-based, not laboratory-based.

Contraindications to Consider:

  • Women with hormone-sensitive breast cancer (use caution; these patients were excluded from trials) 1
  • High cardiometabolic disease risk (safety data lacking in this population) 1

Baseline Assessment Before Initiating Therapy

Before starting testosterone:

  • Measure baseline total testosterone concentration (for monitoring purposes, not diagnosis) 1, 3
  • Complete biopsychosocial assessment to rule out relationship issues, psychological distress, or other treatable causes 1
  • Provide informed consent discussing off-label use, benefits, risks, and lack of long-term safety data beyond 24 months 1, 2

Formulation and Dosing

Use transdermal preparations (patches, gels, or creams) to approximate physiological premenopausal testosterone concentrations 1, 2.

Practical Prescribing Guidance:

  • Preferred: Government-approved female-specific testosterone formulations (where available)
  • When unavailable: Off-label use of approved male transdermal formulations at reduced doses is reasonable 1
  • Avoid: Testosterone pellets, injections, or any preparation causing supraphysiologic levels 1
  • Cannot recommend: Compounded "bioidentical" products due to lack of efficacy and safety data, unless no approved alternative exists 1, 2

The 2019 Global Consensus 1 provides the most current framework, superseding the more restrictive 2014 Endocrine Society guideline 3 which recommended against most testosterone use. The newer evidence supports a more permissive approach for appropriately selected postmenopausal women with HSDD.

Monitoring Protocol

Initial Monitoring:

  • Measure total testosterone at 3-6 weeks after treatment initiation to assess absorption and screen for overuse 1, 3
  • Assess clinical response and signs of androgen excess

Ongoing Monitoring:

  • Check total testosterone every 6 months to ensure levels remain in the physiological premenopausal range 1, 3
  • Monitor for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly)
  • Discontinue therapy if no benefit by 6 months 1

Safety Considerations

Short-term testosterone therapy (up to 24 months) at physiological doses in postmenopausal women:

  • Does not increase serious adverse events 1
  • Does not increase mammographic breast density 1
  • Does not appear to increase breast cancer risk in short-term studies 1

Critical caveat: Long-term safety data beyond 24 months are not available 1. Most trials excluded women at high cardiometabolic risk and included concurrent estrogen therapy, limiting generalizability 1.

What NOT to Use Testosterone For

Do not prescribe testosterone for 3:

  • Infertility
  • Cognitive dysfunction
  • Cardiovascular health
  • Metabolic dysfunction
  • Bone health
  • General well-being or energy
  • Sexual dysfunction other than HSDD
  • Women with hypopituitarism, adrenal insufficiency, or bilateral oophorectomy (unless they also have HSDD)

The evidence does not support these indications, and long-term safety is unestablished.

Common Pitfalls to Avoid

  1. Do not use testosterone levels to diagnose HSDD—symptoms and distress define the condition, not lab values 3
  2. Do not prescribe supraphysiologic doses—pellets and injections typically produce excessive levels 1
  3. Do not skip the biopsychosocial assessment—many cases of low desire have treatable psychological or relationship causes 1
  4. Do not continue therapy beyond 6 months without clinical benefit 1

References

1
Guideline

global consensus position statement on the use of testosterone therapy for women.

The Journal of clinical endocrinology and metabolism, 2019

3
Guideline

androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Related Questions

Can testosterone be prescribed to postmenopausal women with low libido who are not receiving estrogen or progesterone therapy?
How should a healthy adult female with documented low testosterone or hypoactive sexual desire disorder use a 0.2% testosterone cream transdermally, including dosing, application site, monitoring, and contraindications?
What are the current recommendations or guidelines for testosterone therapy in postmenopausal women?
What are the benefits of hormone replacement therapy for female service members or leaders experiencing menopausal symptoms and for male service members or leaders with documented low testosterone?
What benefits does low‑dose testosterone therapy provide for a post‑menopausal woman already receiving estrogen‑based hormone replacement therapy?
What is the recommended inpatient management for a patient with suspected lymphoproliferative disorder versus infectious cervical lymphadenitis who presents with worsening neck pain, progressive dysphagia, contrast‑enhanced neck computed tomography showing diffuse cervical fascial edema, multi‑level cervical adenopathy, fluid tracking in the left parapharyngeal and retropharyngeal spaces, right vocal cord paralysis, and a new papular rash on the lower extremities?
What is the maximal daily dose of hydromorphone for an 88-year-old male with chronic pain syndrome?
What is the appropriate evaluation and management for an elderly patient with oral pain, no obvious abscess, and inability to wear dentures?
When is non‑small cell lung carcinoma considered resectable versus non‑resectable?
Does naltrexone affect the white blood cell count and require routine monitoring?
What are the N1 and N2 lymph‑node stations in the lung?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.